PMC:7195088 / 1225-1809
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 19 | 102-110 | Species | denotes | patients | Tax:9606 |
| 20 | 283-291 | Species | denotes | patients | Tax:9606 |
| 21 | 575-583 | Species | denotes | patients | Tax:9606 |
| 22 | 116-124 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 23 | 566-574 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T9 | 116-124 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T10 | 566-574 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T4 | 22-27 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 22-27 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
| T2 | 28-37 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T3 | 42-65 | Chemical | denotes | anti-inflammatory drugs | http://purl.obolibrary.org/obo/CHEBI_35472 |
| T4 | 60-65 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T5 | 399-405 | Chemical | denotes | Access | http://purl.obolibrary.org/obo/CHEBI_34922 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T13 | 0-12 | Sentence | denotes | Implications |
| T14 | 13-125 | Sentence | denotes | Many off-label antiviral and anti-inflammatory drugs are currently being administered to patients with COVID-19. |
| T15 | 126-398 | Sentence | denotes | Physicians must be aware that, as they are not supported by high-level evidence, these treatments may often be ethically justifiable only in those worsening patients unlikely to improve only with supportive care, and who cannot be enrolled onto randomized clinical trials. |
| T16 | 399-584 | Sentence | denotes | Access to well-designed randomized controlled trials should be expanded as much as possible because it is the most secure way to change for the better our approach to COVID-19 patients. |